Drug intelligence / Profile preview

conjugate 13a

Development stage: Preclinical
Lead developer: Lomonosov Moscow State University
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules

Overview

Conjugate 13a is an investigational **prostate-specific membrane antigen-targeted bimodal small-molecule drug conjugate** reported in a 2023 academic study of targeted therapies for prostate cancer. It incorporates a PSMA-targeting ligand and a cytotoxic monomethyl auristatin E-related antimitotic component within a single covalent construct designed to selectively deliver cytotoxic activity to PSMA-expressing tumor cells. The compound was evaluated in vitro and in PSMA-expressing prostate-cancer xenograft models as a preclinical therapeutic candidate.

Other names: conjugate 13aconjugate13aconjugate-13a

Targets

PSMA (Prostate-specific membrane antigen)ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)

Beyond the preview

Go deeper on conjugate 13a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on conjugate 13a.

Explore the full profile